Without considering the long-term ecological consequences, a short-term oriented biotechnology program is designed to make the viruses carried by insects harmless to humans, which can be achieved by the following steps： --- ###**Program core: Gene Editing and Virus Host Restriction** 1. **Target key genes of the virus** - Use CRISPR-Cas9 or other gene editing tools to knock out or modify genes in the viral genome that are related to human cell infection (such as genes encoding host receptor binding proteins). -For example, for mosquito-borne viruses (such as Dengue fever and Zika virus), the coding sequence of their envelope protein (E protein) is destroyed, making it unable to recognize and invade human cells. 2. **Insect genetic modification** -**Strengthen the insect immune system**: Edit insect genes to express antiviral proteins (such as RNAi or antiviral antibodies) to inhibit the replication of viruses in insects. -**Introduction of “virus blocking genes"**: Through transgenic technology, the salivary glands or digestive system of insects are allowed to express enzymes (such as proteases or nucleases) that can degrade virus particles and inactivate the virus before it spreads to humans. 3. **Symbiotic microbial engineering** -Transform symbiotic bacteria in insects (such as Wolbachia) to secrete antiviral molecules (such as cytokines or small molecule inhibitors) to directly neutralize viral particles without affecting insect health. --- ###**Short-term implementation strategy** 1. **Gene drive diffusion** -Combine the above-mentioned antiviral genes with the Gene Drive system to quickly spread antiviral properties to the entire insect population through population genetics, covering areas at high risk of transmission in a short period of time. 2. **Targeted virus weakening** -Design** Conditions to weaken the virus** (Attenuated Virus) so that it can only survive in insects, but cannot replicate under human body temperature or physiological conditions. 3. **Delivery system optimization** -The use of nano-particles or viral vectors to directly introduce antiviral genes into insect populations in the wild, without the need for large-scale laboratory reproduction. --- ###**Risk aversion (short-term perspective)** - **Host-specific enhancement**: Ensure that the virus only retains the ability to infect insect cells (such as relying on insect-specific promoter or host factor). - **Gene redundancy design**: For escape mutations that may occur in the virus, multiple key genes are edited at the same time to reduce the probability of restoring virulence. --- ###**Conclusion** The program uses gene editing and host restriction technology to block the path of virus transmission to humans in the short term, but the following assumptions need to be clarified： 1. Insect population size can be controlled, gene drive will not accidentally spread to non-target species； 2. The stability of the virus is high after gene editing, and the risk of mutation escape is extremely low.； 3. Ignore the potential impact on ecological chains (such as insect-dependent species such as birds and amphibians). This plan focuses on technical feasibility, and the long-term consequences need to be evaluated separately.